GRM5 and major depressive disorder: Therefore, mGluR5s have been recently considered as a new target of novel antidepressants, and basimglurant, a negative allosteric modulator of mGluR5, is now in clinical development for the treatment of MDD (NCT00809562 and NCT01437657).